Medicure (TSE:MPH) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medicure Inc. has signed an agreement to acquire intellectual property from CanAm Bioresearch Inc., focusing on new chemical entities with potential therapeutic applications. The deal includes an initial cash payment and additional milestone payments upon filing and approval of new drug applications. Medicure expects these acquisitions to enhance its pharmaceutical development and commercialization efforts in the United States.
For further insights into TSE:MPH stock, check out TipRanks’ Stock Analysis page.